Actinium Pharmaceuticals, Inc. (ATNM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ATNM currently has 31.2M outstanding shares. with moderate dilution risk from 10.6M authorized shares representing 33.8% potential dilution. The company has minimally diluted shareholders by 7.09% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
10-Q filing | 31.2M shares outstanding |
31M | 11M |
| Mar 30, 2026 |
10-K filing | 31.2M shares outstanding |
31M | 11M |
| Nov 14, 2025 |
10-Q filing | 31.2M shares outstanding |
31M | 11M |
| May 09, 2025 |
10-Q filing | 31.2M shares outstanding |
31M | 11M |
| Mar 31, 2025 |
10-K filing | 30.1M shares outstanding |
30M | 12M |
| Nov 14, 2024 |
10-Q filing | 31.1M shares outstanding |
31M | 11M |
| Aug 05, 2024 |
10-Q filing | 30.1M shares outstanding |
30M | 12M |
| Apr 26, 2024 |
10-Q filing | 27.9M shares outstanding |
28M | 14M |
| Mar 29, 2024 |
10-K filing | 26.6M shares outstanding |
27M | 15M |
| Feb 02, 2024 |
S-3/A filing: Actinium Pharmaceuticals intends to offer and sell common stock having an aggregate offering price of up to $200,000,000 from time to time through or to JonesTrading and B.Riley Securities as part of an at-the-market offering. |
27M | 15M |
| Nov 02, 2023 |
10-Q filing | 27.1M shares outstanding |
27M | 0 |
| Aug 14, 2023 |
10-Q filing | 26.2M shares outstanding |
26M | 0 |
| Aug 11, 2023 |
S-3 filing: Actinium Pharmaceuticals, Inc. is offering up to $200,000,000 of its common stock from time to time through an at-the-market offering. |
26M | 0 |
| May 15, 2023 |
10-Q filing | 25.7M shares outstanding |
26M | 0 |
| Mar 31, 2023 |
10-K filing | 24.1M shares outstanding |
24M | 0 |
| Nov 14, 2022 |
10-Q filing | 25.2M shares outstanding |
25M | 0 |
| Aug 12, 2022 |
10-Q filing | 23.7M shares outstanding |
24M | 0 |
| May 13, 2022 |
10-Q filing | 22.1M shares outstanding |
22M | 0 |
| Mar 25, 2022 |
10-K filing | 22.1M shares outstanding |
22M | 0 |
| Nov 12, 2021 |
10-Q filing | 22.0M shares outstanding |
22M | 0 |
| Jul 30, 2021 |
10-Q filing | 21.3M shares outstanding |
21M | 0 |
| May 14, 2021 |
10-Q filing | 20.2M shares outstanding |
20M | 0 |
| Mar 31, 2021 |
10-K filing | 19.2M shares outstanding |
19M | 0 |
| Oct 23, 2020 |
10-Q filing | 13.6M shares outstanding |
14M | 0 |
| Aug 14, 2020 |
10-Q filing | 13.2M shares outstanding |
13M | 160M |
| Aug 10, 2020 |
Stock Split
8-K filing: Stock split 1-for-30 | Outstanding: 174,839,536 → 5,827,984 |
5.8M | 0 |
| Aug 07, 2020 |
S-3 filing: Actinium Pharmaceuticals, Inc. files an S-3 form to offer and sell up to $500,000,000 of common stock, preferred stock and/or subscription rights in one or more offerings. |
170M | 0 |
| Jun 29, 2020 |
10-Q filing | 174.8M shares outstanding |
170M | 0 |
| Jun 18, 2020 |
8-K filing: Actinium Pharmaceuticals, Inc. commenced and priced a public offering of 76,923,077 shares of common stock (or Common Stock equivalents) at $0.3250 per share, with net proceeds expected to be approximately $22.8 million. ($25.0M proceeds) |
120M | 0 |
| May 08, 2020 |
10-K filing | 115.7M shares outstanding |
120M | 0 |
| Apr 24, 2020 |
8-K filing: Actinium Pharmaceuticals closed a public offering on April 24, 2020, issuing 183,333,334 shares of common stock (or pre-funded warrants) with an additional 27,500,000 shares through the underwriter's option, at a price of $0.15 per share, resulting in gross proceeds of approximately $31.6 million before deducting expenses. ($31.6M proceeds) |
N/A | 0 |